Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin 18 pseudogene 41 (KRT18P41) is classified as a processed pseudogene derived from the keratin 18 gene. Pseudogenes like KRT18P41 do not code for functional proteins and do not serve as therapeutic drug targets[1]. While its parent gene, Keratin 18 (KRT18), is a major epithelial intermediate filament protein with roles in cancer biomarker discovery and cell death processes[2][3], KRT18P41 lacks the intact genetic sequence needed to be expressed as protein and is not implicated in disease or targeted for therapy. There is no evidence to support its utility in patient selection, efficacy monitoring, or as a clinical safety concern. Notably, various pseudogenes for keratins exist throughout the human genome, frequently cataloged for nomenclature purposes, but they are nonfunctional and have no established physiological or pathogenic significance[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratin 18 pseudogene 41 (KRT18P41).